Historique
Périodique
Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine
(Etude comparative de deux méthodes de sevrage d'opiacés par la loféxidine et la buprénorphine)
Auteur(s) :
R. WHITE ;
R. ALCORN ;
C. FEINMANN
Article en page(s) :
77-83
Refs biblio. :
31
Domaine :
Drogues illicites / Illicit drugs
Langue(s) :
Anglais
Thésaurus mots-clés
BUPRENORPHINE
;
OPIACES
;
CLONIDINE
;
TRAITEMENT AMBULATOIRE
;
SYNDROME DE SEVRAGE
;
COMPARAISON
;
EFFICACITE
Note générale :
Drug and Alcohol Dependence, 2001, 65, (1), 77-83
Note de contenu :
tabl. ; graph.
Résumé :
ENGLISH :
There is currently no consensus on the best approach to the management of opiate detoxification. In the current open-label study, 69 opiate-dependent individuals requesting outpatient detoxification were allocated to two different medication regimes: lofexidine and buprenorphine. Allocation was dependent on the timing of their presentation. Lofexifidine is a structural analogue of clonidine, and used widely in the UK. Buprenorphine is a partial opiate agonist with unusual pharmacological properties. Outcomes were better for the buprenorphine-receiving group (n=38). Clients receiving buprenorphine had a less severe withdrawal syndrome, and were more likely to complete their detoxification. In addition, for the buprenorphine-receiving group it was found that the withdrawal syndrome was least in those prescribed an initial dose of 4 mg. The findings and their implications are discussed. The design of the study precludes definitive conclusions regarding relative efficacy. (Author's abstract.)
ENGLISH :
There is currently no consensus on the best approach to the management of opiate detoxification. In the current open-label study, 69 opiate-dependent individuals requesting outpatient detoxification were allocated to two different medication regimes: lofexidine and buprenorphine. Allocation was dependent on the timing of their presentation. Lofexifidine is a structural analogue of clonidine, and used widely in the UK. Buprenorphine is a partial opiate agonist with unusual pharmacological properties. Outcomes were better for the buprenorphine-receiving group (n=38). Clients receiving buprenorphine had a less severe withdrawal syndrome, and were more likely to complete their detoxification. In addition, for the buprenorphine-receiving group it was found that the withdrawal syndrome was least in those prescribed an initial dose of 4 mg. The findings and their implications are discussed. The design of the study precludes definitive conclusions regarding relative efficacy. (Author's abstract.)
Affiliation :
St Lukes Woodside Hosp., Woodside Av., Muswell Hill, London N10 3HU
Royaume-Uni. United Kingdom.
Royaume-Uni. United Kingdom.
Exemplaires
| Disponibilité |
|---|
| aucun exemplaire |